Triplex formation by morpholino oligodeoxyribonucleotides in the HER-2/neu promoter requires the pyrimidine motif

door Basye, Jenny, Trent, John O., Gao, Daquan, Ebbinghaus, Scot W.
Gepubliceerd in 2001

Formation of a unique end-to-end stacked pair of G-quadruplexes in the hTERT core promoter with implications for inhibition of telomerase by G-quadruplex-interactive ligands

door Palumbo, SunMi L., Ebbinghaus, Scot W., Hurley, Laurence H.
Gepubliceerd in 2009

Pembrolizumab

door Khoja, Leila, Butler, Marcus O., Kang, S. Peter, Ebbinghaus, Scot, Joshua, Anthony M.
Gepubliceerd in J Immunother Cancer (2015)

Proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure which can be targeted by G-quadruplex-interactive agents

door Sun, Daekyu, Liu, Wei-Jun, Guo, Kexiao, Rusche, Jadrian J., Ebbinghaus, Scot, Gokhale, Vijay, Hurley, Laurence H.
Gepubliceerd in 2008

Patient and Oncology Nurse Preferences for the Treatment Options in Advanced Melanoma: A Discrete Choice Experiment

door Liu, Frank Xiaoqing, Witt, Edward A., Ebbinghaus, Scot, DiBonaventura Beyer, Grace, Basurto, Enrique, Joseph, Richard W.
Gepubliceerd in Cancer Nurs (2019)

A novel G-quadruplex-forming GGA repeat region in the c-myb promoter is a critical regulator of promoter activity

door Palumbo, SunMi L., Memmott, Regan M., Uribe, Diana J., Krotova-Khan, Yulia, Hurley, Laurence H., Ebbinghaus, Scot W.
Gepubliceerd in 2008

Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment

door Liu, Frank Xiaoqing, Witt, Edward A, Ebbinghaus, Scot, DiBonaventura Beyer, Grace, Shinde, Reshma, Basurto, Enrique, Joseph, Richard W
Gepubliceerd in Patient Prefer Adherence (2017)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices

door Cowey, C. Lance, Liu, Frank Xiaoqing, Black-Shinn, Jenny, Stevinson, Kendall, Boyd, Marley, Frytak, Jennifer R., Ebbinghaus, Scot W.
Gepubliceerd in J Immunother (2018)

Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

door Wang, Meihua, Chen, Cong, Jemielita, Thomas, Anderson, James, Li, Xiaoyun (Nicole), Hu, Chen, Kang, S. Peter, Ibrahim, Nageatte, Ebbinghaus, Scot
Gepubliceerd in J Immunother Cancer (2019)

Repair of triplex-directed DNA alkylation by nucleotide excision repair

door Ziemba, Amy, Derosier, L. Chris, Methvin, Russell, Song, Chun-Yan, Clary, Eric, Kahn, Wendy, Milesi, David, Gorn, Vladimir, Reed, Mike, Ebbinghaus, Scot
Gepubliceerd in 2001

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors

door Ayers, Mark, Lunceford, Jared, Nebozhyn, Michael, Murphy, Erin, Loboda, Andrey, Albright, Andrew, Cheng, Jonathan, Kang, S Peter, Ebbinghaus, Scot, Yearley, Jennifer, Shankaran, Veena, Seiwert, Tanguy, Ribas, Antoni, McClanahan, Terri
Gepubliceerd in J Immunother Cancer (2015)

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group

door Harvey, R. Donald, Mileham, Kathryn F., Bhatnagar, Vishal, Brewer, Jamie, Rahman, Atiqur, Moravek, Cassadie, Kennedy, Andrew S., Ness, Elizabeth A., Dees, E. Claire, Ivy, S. Percy, Ebbinghaus, Scot, Schenkel, Caroline, Uldrick, Thomas S.
Gepubliceerd in Clin Cancer Res (2021)

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

door Hamid, Omid, Robert, Caroline, Ribas, Antoni, Hodi, F. Stephen, Walpole, Euan, Daud, Adil, Arance, Ana S., Brown, Ewan, Hoeller, Christoph, Mortier, Laurent, Schachter, Jacob, Long, Jianmin, Ebbinghaus, Scot, Ibrahim, Nageatte, Butler, Marcus
Gepubliceerd in Br J Cancer (2018)

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

door Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony
Gepubliceerd in 2012

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

door Gangadhar, Tara C., Hwu, Wen-Jen, Postow, Michael A., Hamid, Omid, Daud, Adil, Dronca, Roxana, Joseph, Richard, O’Day, Steven J., Hodi, F.S., Pavlick, Anna C., Kluger, Harriet, Oxborough, Romina P., Yang, Aiming, Gazdoiu, Mihaela, Kush, Debra A., Ebbinghaus, Scot, Salama, April K.S.
Gepubliceerd in J Immunother (2017)

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

door Di Cosimo, Serena, Sathyanarayanan, Sriram, Bendell, Johanna C., Cervantes, Andrés, Stein, Mark N., Braña, Irene, Roda, Desamparados, Haines, Brian B., Zhang, Theresa, Winter, Christopher G., Jha, Sharda, Xu, Youyuan, Frazier, Jason, Klinghoffer, Richard A., Leighton-Swayze, Ann, Song, Yang, Ebbinghaus, Scot, Baselga, José
Gepubliceerd in Clin Cancer Res (2014)

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

door Baselga, José, Morales, Serafin M., Awada, Ahmad, Blum, Joanne L., Tan, Antoinette R., Ewertz, Marianne, Cortes, Javier, Moy, Beverly, Ruddy, Kathryn J., Haddad, Tufia, Ciruelos, Eva M., Vuylsteke, Peter, Ebbinghaus, Scot, Im, Ellie, Eaton, Lamar, Pathiraja, Kumudu, Gause, Christine, Mauro, David, Jones, Mary Beth, Rugo, Hope S.
Gepubliceerd in Breast Cancer Res Treat (2017)

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

door Dummer, Reinhard, Daud, Adil, Puzanov, Igor, Hamid, Omid, Schadendorf, Dirk, Robert, Caroline, Schachter, Jacob, Pavlick, Anna, Gonzalez, Rene, Hodi, F Stephen, Cranmer, Lee D, Blank, Christian, O’Day, Steven J, Ascierto, Paolo A, Salama, April K S, Li, Nicole Xiaoyun, Zhou, Wei, Lis, Joy, Ebbinghaus, Scot, Kang, Peter S, Ribas, Antoni
Gepubliceerd in J Transl Med (2015)

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

door Hodi, F. Stephen, Hwu, Wen-Jen, Kefford, Richard, Weber, Jeffrey S., Daud, Adil, Hamid, Omid, Patnaik, Amita, Ribas, Antoni, Robert, Caroline, Gangadhar, Tara C., Joshua, Anthony M., Hersey, Peter, Dronca, Roxana, Joseph, Richard, Hille, Darcy, Xue, Dahai, Li, Xiaoyun Nicole, Kang, S. Peter, Ebbinghaus, Scot, Perrone, Andrea, Wolchok, Jedd D.
Gepubliceerd in J Clin Oncol (2016)

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC)

door Hodi, F Stephen, Ribas, Antoni, Daud, Adil, Hamid, Omid, Robert, Caroline, Kefford, Richard, Hwu, Wen-Jen, Gangadhar, Tara C, Joshua, Anthony M, Hersey, Peter, Weber, Jeffrey, Joseph, Richard W, Zarour, Hassane, Dronca, Roxana, Gammage, Linda, Hille, Darcy, Xue, Dahai, Kang, S Peter, Chun, Patrick, Ebbinghaus, Scot W, Perrone, Andrea, Wolchok, Jedd D
Gepubliceerd in J Immunother Cancer (2014)